Reporting and Reconciliation. For transactions provided for under this Agreement, EZCheck will provide Merchant with transaction volume reporting and transaction fee record keeping in a format and manner to be determined by EZCheck. Merchant agrees to notify EZCheck promptly of any discrepancies between Merchant’s records or bank statements and the information in the reports provided by EZCheck. If Merchant fails to notify EZCheck within 60 days of the transaction of any such discrepancy or funding error, Merchant shall be precluded from asserting any losses, claims or liability against EZCheck arising from such discrepancies or errors.
Reporting and Reconciliation. Ablynx shall, within […***…] following the end of the first Research Term Year during the Research Program Term and thereafter […***…] following that date, deliver to Merck a written report detailing the number of FTEs actually utilized during said Research Term Year for the performance of Research Program activities under such Research Program, including a description of the activities performed (and Merck shall have the right to audit Ablynx’s records in connection therewith in accordance with Section 5.8, mutatis mutandis). […***…], then at the end of said Research Term Year, Ablynx shall invoice Merck for the additional FTEs actually utilized during said Research Term Year in accordance with the applicable FTE rate, and Merck shall pay the invoiced amount within […***…] from receipt of said invoice. For clarity, in no event shall Ablynx be entitled to receive payment for (and Ablynx shall be solely responsible for) any and all FTEs which are in excess of the number of FTEs authorized to be utilized to conduct the Research Program activities during such period as set forth in the applicable Work Plans.
Reporting and Reconciliation. Wherever possible and practicable, prior to any Funding Event any external Shared Development Costs incurred in accordance with the binding parts of the Development Budget shall initially be invoiced to and borne by Pfizer, but shall be subject to reimbursement in accordance with this Section 5.4.4. All other Shared Development Costs incurred in accordance with the binding parts of the Development Budget shall initially be borne by the Party incurring such costs and shall thereafter be subject to reimbursement in accordance with this Section 5.4.4. Each Party shall report to the other Party, within [***] after the end of each Pfizer US Quarter, the Shared Development Costs incurred by such Party during such Pfizer Quarter. Such report shall specify in reasonable detail all amounts included in such Shared Development Costs during such Pfizer Quarter (broken down by activity), and out-of-pocket costs shall be allocated to the extent possible to a specific activity in the applicable binding part of the Research and Development Plan. Each such report shall enable the receiving Party to compare the reported Shared Development Costs against the applicable binding part of the Development Budget previously approved by the JSC, on both a quarterly basis and a cumulative basis for each activity. The Parties shall seek to resolve any questions related to such accounting statements within [***] following receipt by each Party of the other Party’s report hereunder. Following such resolution, BioNTech shall prepare a reconciliation report for the Shared Development Costs for such Pfizer Quarter (including as against the binding parts of the Development Budget) and shall either (a) deliver an invoice to Pfizer for any amounts due to BioNTech as a result of reconciliation or (b) notify Pfizer that it should issue an invoice to BioNTech for any amounts due to Pfizer as a result of reconciliation. Any such invoice from BioNTech to Pfizer shall be payable within [***] from receipt by Pfizer. Prior to any Funding Event, any such invoice from Pfizer to BioNTech shall not be payable upon receipt, but shall be accounted as BioNTech Deferred Development Costs and shall be payable in accordance with the mechanism described in Section 5.4.2. Following any Funding Event, any such such invoice from Pfizer to BioNTech shall be payable within [***] from receipt by Pfizer.
Reporting and Reconciliation. Ambrx shall, within forty-five (45) days following the end of each Calendar Quarter during the Research Term, deliver to Agensys a written report detailing the number of FTEs actually utilized in such Calendar Quarter for the performance of Research Program activities and MTA activities, including a description of the activities performed (and Agensys shall have the right to audit Ambrx’s records in connection therewith in accordance with Section 5.6, mutatis mutandis). In the event that the number of FTEs actually utilized in such Calendar Quarter is less than the number of FTEs for which Agensys made payment in advance pursuant to Section 5.1, 5.2.1, or 5.2.2, then at Agensys’ option, Ambrx shall either refund or credit Agensys for the difference between the payment made by Agensys and the actual payment due for such FTEs (provided that if Agensys opts for a refund, such refund shall be made by Ambrx within thirty (30) days following notice by Agensys thereof and if Agensys opts for a credit, Agensys shall be entitled to a credit against any future FTE amounts payable by Agensys pursuant to this Section 5.2). For clarity, in no event shall Ambrx be entitled to receive payment for (and Ambrx shall be solely responsible for) any and all FTEs in a given Calendar Quarter which are in excess of the number of FTEs authorized to be utilized to conduct the Research Program activities in such Calendar Quarter as set forth in the Research Plan, an MTA or as otherwise expressly approved in writing by the JPT. In all events Ambrx shall be entitled to receive payment for at least two (2) FTEs in a given Calendar Quarter.
Reporting and Reconciliation. (i) Within sixty (60) days after the end of each calendar quarter following the first receipt of revenues under this Agreement (which may be either from Net Sales or Licensing Revenue), Nuvelo shall prepare and submit to Archemix a statement of quarterly Product Profit and Loss, prepared on an accrual basis in accordance with GAAP in substantially the form attached as Exhibit H, which shall include a calculation of the equalization payment which is necessary to cause the ratio of the participation of Nuvelo and Archemix in the Product Profit and Loss for such quarter on an accrual basis to be seventy-five percent/twenty-five percent (75%/25%), respectively (the “Financial Statement”). The reports and equalization payments for the fourth quarter of the fiscal year may include reconciliations and year-end adjustments with respect to previous quarters. All payments required by this Section 7.5 shall be made concurrently with the submittal of the Financial Statement or, if a payment is due from Archemix to Nuvelo, within ten (10) days after receipt thereof by Archemix. Nuvelo will provide to Archemix such supporting information for the Financial Statement as Archemix may reasonably request. Archemix may audit, in accordance with the procedures set forth in Article 8, the accuracy of Nuvelo’s submissions pursuant to this Section 7.5(b)(i).
Reporting and Reconciliation. Within 30 days after the Effective Date, NewCo and Microsoft will agree on a quarterly reporting mechanism to exchange information about the gross revenue portion of Net Revenue that each party transacts during the prior quarter, the information necessary to calculate Net Revenue for such period, as well as any remittances it made to the other during such period. Within 30 days after the Effective Date, NewCo and Microsoft will also agree on a quarterly true-up process to validate (a) the total Net Revenue for such period, (b) the cumulative Revenue Share Service Fee paid to Microsoft to date for the relevant Contract Year, and (c) any further remittances by NewCo to Microsoft needed to pay unpaid Revenue Share Service Fees payable for the relevant Contract Year in accordance with Section 7.2. NewCo and Microsoft will agree on a mechanism for submitting any such remittances required as a result of this true-up process. Any disputes related to Section 7.2.2 or this Section 7.3 (to the extent related thereto) will be resolved through Formal Escalation and, if that does not resolve the dispute, Expedited Arbitration.
Reporting and Reconciliation. Ambrx shall, within [***] days following the end of each Calendar Quarter during the Research Program Term, deliver to Merck a ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. written report detailing the number of FTEs actually utilized in such Calendar Quarter for the performance of Research Program activities, including a description of the activities performed (and Merck shall have the right to audit Ambrx’s records in connection therewith in accordance with Section 5.7, mutatis mutandis). In the event that the number of FTEs actually utilized in such Calendar Quarter is less than the number of FTEs for which Merck made payment in advance pursuant to Section 5.2.1, then at Merck’s option, Ambrx shall either refund or credit Merck for the difference between the payment made by Merck and the actual payment due for such FTEs (provided that if Merck opts for a refund, such refund shall be made by Ambrx within [***] days following notice by Merck thereof and if Merck opts for a credit, Merck shall be entitled to a credit against any future FTE amounts payable by Merck pursuant to this Section 5.2). For clarity, in no event shall Ambrx be entitled to receive payment for (and Ambrx shall be solely responsible for) any and all FTEs in a given Calendar Quarter which are in excess of the number of FTEs authorized to be utilized to conduct the Research Program activities in such Calendar Quarter as set forth in the applicable Research Plan or as otherwise expressly approved in writing by the Committee.
Reporting and Reconciliation. (i) Within [*] in which there is a Collaboration Product for which one or both Parties are attempting to negotiate a Partnering Agreement pursuant to this Section 6.2, each Party shall report to the JOC or (JFC, if formed) the total of all Partnering Costs it incurred in such quarter with respect to such Collaboration Product. If one Party incurred more such Partnering Costs during such quarter, then the JOC shall promptly send the other Party an invoice for [*]. The other Party shall pay the amount of such invoice to the first Party within [*] of the date of such invoice.
Reporting and Reconciliation. (i) Within [*] in which there is a PPD Terminated Product for which Syrrx is attempting to negotiate a Partnering Agreement pursuant to this Section 6.4, Syrrx shall report to the JOC or (JFC, if formed) the total of all Partnering Costs it incurred in such quarter with respect to such Collaboration Product. The JOC or (JFC, if formed) shall keep such information for calculating payments pursuant to Section 6.4(d)(ii).
Reporting and Reconciliation. The NUECES COUNTY CLERK will be responsible for maintaining and reconciling their receipts. Documents will not be accepted if not accompanied by EFT information. ELECTRONIC RECORDING PROVIDER will be responsible for submitting EFT information with each document batch, and for reconciling their records. Requirements: The ELECTRONIC RECORDING PROVIDER will establish a daily notification system to the NUECES COUNTY CLERK of EFT payment. Exception Handling Any discrepancy in fees discovered by the COUNTY after document acceptance will be corrected by ELECTRONIC RECORDING PROVIDER within five business days of notification of the error. Failure to timely pay fees due in full may result in the immediate suspension of this Agreement at the sole discretion of the County Clerk. This does not waive nor shall it preclude the County Clerk or County from pursuing any and all legal remedies available against the Electronic Recording Provider or Authorized Filer. Attachment E PRIA Document Codes Doc Type Doc Code ABSTRACT OF JUDGMENT ABSTRACT OF JUDGMENT ADDENDUM ADDENDUM AFFIDAVIT AFFIDAVIT AGREEMENT AGREEMENT AMENDMENT AMENDMENT APPOINTMENT APPOINTMENT ASSESSMENT ASSESSMENT ASSIGNMENT ASSIGNMENT ATRICLES ARTICLES BANKRUPTCY BANKRUPTCY XXXX OF SALE XXXX OF SALE BOND BOND BY-LAWS BY-LAWS CERTIFICATE CERTIFICATE CHILD SUPPORT LIEN CHILD SUPPORT LIEN CONSENT CONSENT CONTRACT CONTRACT DEATH DEATH DECLARATION DECLARATION DEED DEED DEED OF TRUST DEED OF TRUST DESIGNATION DESIGNATION DIRECTIVE DIRECTIVE DISCHARGE DISCHARGE DISTRIBUTION DISTRIBUTION DIVORCE DIVORCE EASEMENT EASEMENT EXTENSION EXTENSION FED TAX LIEN RELEASE FED TAX LIEN RELEASE FEDERAL TAX LIEN FEDERAL TAX LIEN FINANCING STATEMENT FINANCING STATEMENT HOME EQUITY HOME EQUITY JUDGMENT JUDGMENT LEASE LEASE XXXX XXXX LIS PENDEN LIS PENDEN MARRIAGE MARRIAGE MECHANICS LIEN MECHANICS LIEN MEMORANDUM MEMORANDUM MERGER MERGER MINERAL DEED MINERAL DEED MISCELLANEOUS MISCELLANEOUS MODIFICATION MODIFICATION NOTICE NOTICE ORDER ORDER PARTIAL RELEASE PARTIAL RELEASE PERMIT PERMIT POWER OF ATTORNEY POWER OF ATTORNEY PROBATE PROBATE QUITCLAIM QUITCLAIM RATIFICATION RATIFICATION RECONVEYANCE RECONVEYANCE REINSTATEMENT REINSTATEMENT RELEASE RELEASE RENEWAL RENEWAL RESCISSION RESCISSION RESIGNATION RESIGNATION RESOLUTION RESOLUTION RESTRICTIONS RESTRICTIONS REVOCATION REVOCATION RIGHT FIRST REFUSAL RIGHT OF FIRST REFUSAL SATISFACTION SATISFACTION SECURITY DOCUMENT SECURITY DOCUMENT STATE TAX LIEN STATE TAX LIEN STATE TAX LIEN RELST...
